Research Journal of Pharmacology and Pharmacodynamics

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Infantile Refsum Disease and its Treatment


Affiliations
1 Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt), Andhrapradesh, India
2 Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt), Andhrapradesh, India
     

   Subscribe/Renew Journal


Infantile Refsum disease (IRD) also called infantile phytanic acid storage disease is a rare autosomal recessive congenital peroxisomal biogenesis disorder (PBD). First it was discovered by Norwegian neurologist, Sigvald Refsum. Refsum disease also has a Latin name, heredopathia atactica polyneuritiformis, meaning a hereditary disease affecting balance and the peripheral nerves. There are four types of PBDs - Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD) and rhizomelic chondrodysplasia punctata (RCDP). Mainly it occurs due to elevated plasma concentration of phytanic acid. Blood levels of phytanic acid are increased in patients with Refsum disease. These levels are 10-50 mg/dL, whereas normal values are less than or equal to 0.2 mg/dL. Some of the causes of this disease are muscle conditions,brain conditions, genetic variations. The main symptoms are Visual impairments, Retinitis pigmentosa and hearing impairments. IRD is definitively confirmed with biochemical evaluation. Diagnosis of IRD before birth is possible by genetic testing. The main differential diagnoses include Usher syndrome I and II. The main complication of this disease is Cardiac involvement i.e. produce conduction abnormalities and cardiomyopathy has been associated with premature death. Mainly it is treated by dietary restriction. Another common approach is in supplementing the child's diet with docosahexaenoic acid (DHA).

Keywords

Infantile Refsum Disease, Zellweger Syndrome, Phytanic Acid, Retinitis Pigmentosa and Cardiomyopathy.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Jansen GA, Ofman R, Ferdinandusse S, et al. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nat Genet. Oct 1997;17(2):190-3. [Medline].

  • Singh I, Pahan K, Singh AK, Barbosa E. Refsum disease: a defect in the alpha-oxidation of phytanic acid in peroxisomes. J Lipid Res. Oct 1993;34(10):1755-64. [Medline].

  • Wanders RJ, Komen J, Ferdinandusse S. Phytanic acid metabolism in health and disease. Biochim Biophys Acta. Sep 2011;1811(9):498-507. [Medline].

  • Komen JC, Distelmaier F, Koopman WJ, Wanders RJ, Smeitink J, Willems PH. Phytanic acid impairs mitochondrial respiration through protonophoric action. Cell Mol Life Sci. Dec 2007;64(24):3271-81.[Medline].

  • Foulon V, Asselberghs S, Geens W, Mannaerts GP, Casteels M, Van Veldhoven PP. Further studies on the substrate spectrum of phytanoyl-CoA hydroxylase: implications for Refsum disease?. J Lipid Res. Dec 2003;44(12):2349-55. [Medline].

  • James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology (10th ed.). Saunders. p. 564. ISBN 0-7216-2921-0.

  • Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 1-4160-2999-0.

  • Jayaram, H.; Downes, S. M. (March 2008). "Midlife diagnosis of Refsum Disease in siblings with Retinitis Pigmentosa - the footprint is the clue: a case report". Journal of Medical Case Reports (Free full text) 2: 80. doi:10.1186/1752-1947-2-80.PMC 2275283. PMID 18336720. edit.

  • Refsum S (1945). "Heredoataxia hemeralopica polyneuritiformis - et tidligere ikke beskrevet familirt syndrom? En forelobig meddelelse". Nordisk Medicin (in Norwegian) 28: 2682-6.

  • Refsum S (1946). "Heredopathia atactica polyneuritiformis. A familial syndrome not hitherto described. A contribution to the clinical study of hereditary diseases of the nervous system". Acta psych. neur. (Suppl.38): 1-303.

  • Coppack SW, Evans R, Gibberd FB, et al; Can patients with Refsum's disease safely eat green vegetables? Br Med J (Clin Res Ed). 1988 Mar 19; 296(6625):828.

  • Zalewska A et al, Refsum Disease, Medscape, Jul 2009.

  • Siegmund JB, Meier H, Hoppmann I, et al; Cascade filtration in Refsum's disease. Nephrol Dial Transplant. 1995; 10(1):117-9.

  • www.rightdiagnosis.com.

  • en.wikipedia.org.

  • www.ninds.nih.gov.

  • www.orpha.net.


Abstract Views: 234

PDF Views: 0




  • Infantile Refsum Disease and its Treatment

Abstract Views: 234  |  PDF Views: 0

Authors

D. Rajesh Kumar
Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt), Andhrapradesh, India
L. Manipriya
Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt), Andhrapradesh, India
M. Radhika
Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt), Andhrapradesh, India
S. Anusha
Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt), Andhrapradesh, India

Abstract


Infantile Refsum disease (IRD) also called infantile phytanic acid storage disease is a rare autosomal recessive congenital peroxisomal biogenesis disorder (PBD). First it was discovered by Norwegian neurologist, Sigvald Refsum. Refsum disease also has a Latin name, heredopathia atactica polyneuritiformis, meaning a hereditary disease affecting balance and the peripheral nerves. There are four types of PBDs - Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD) and rhizomelic chondrodysplasia punctata (RCDP). Mainly it occurs due to elevated plasma concentration of phytanic acid. Blood levels of phytanic acid are increased in patients with Refsum disease. These levels are 10-50 mg/dL, whereas normal values are less than or equal to 0.2 mg/dL. Some of the causes of this disease are muscle conditions,brain conditions, genetic variations. The main symptoms are Visual impairments, Retinitis pigmentosa and hearing impairments. IRD is definitively confirmed with biochemical evaluation. Diagnosis of IRD before birth is possible by genetic testing. The main differential diagnoses include Usher syndrome I and II. The main complication of this disease is Cardiac involvement i.e. produce conduction abnormalities and cardiomyopathy has been associated with premature death. Mainly it is treated by dietary restriction. Another common approach is in supplementing the child's diet with docosahexaenoic acid (DHA).

Keywords


Infantile Refsum Disease, Zellweger Syndrome, Phytanic Acid, Retinitis Pigmentosa and Cardiomyopathy.

References